Alcon (ALC)
(Delayed Data from NYSE)
$78.77 USD
-0.07 (-0.09%)
Updated Apr 26, 2024 04:00 PM ET
After-Market: $78.79 +0.02 (0.03%) 7:58 PM ET
3-Hold of 5 3
C Value C Growth A Momentum B VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$78.77 USD
-0.07 (-0.09%)
Updated Apr 26, 2024 04:00 PM ET
After-Market: $78.79 +0.02 (0.03%) 7:58 PM ET
3-Hold of 5 3
C Value C Growth A Momentum B VGM
Zacks News
Alcon (ALC) Stock Up 9.7% YTD: Will the Rally Continue?
by Zacks Equity Research
Alcon (ALC) continues gaining from the company's diverse portfolio, incremental innovation, and new product launches.
Here's Why You Should Hold Centene (CNC) in Your Portfolio
by Zacks Equity Research
Robust revenue growth outlook, contract wins, accretive acquisitions and streamlining of businesses poise Centene (CNC) well for growth.
Alcon (ALC) Gains From Growing Market Demand, New Launches
by Zacks Equity Research
Within Vision Care, Alcon (ALC) is registering solid growth, banking on strong sales of its contact lenses and ocular health products.
Centene (CNC) Eyes Membership Growth With 2024 Expansion Plans
by Zacks Equity Research
Centene (CNC) declares the availability of a varied set of health plans across new counties in 2024. It, thereby, places intensified focus on growing its Medicare business.
Alcon (ALC) Expands Optical Care Line With Latest Launch
by Zacks Equity Research
Alcon's (ALC) new TOTAL30 Multifocal lens outwits digital device dryness by delivering nearly 100% water at the lens's surface via a patented Water Gradient Technology.
Is Alcon (ALC) Stock Outpacing Its Medical Peers This Year?
by Zacks Equity Research
Here is how Alcon (ALC) and Cardinal Health (CAH) have performed compared to their sector so far this year.
Waters (WAT) Boosts Mass Spectrometry Clientele With Latest Move
by Zacks Equity Research
Waters (WAT) partners with the University of San Agustin to provide the latter with technology equipment in its newly developed mass spectrometry imaging center in the Philippines.
Humana's (HUM) 2024 MA Plans Promise a Wider Set of Benefits
by Zacks Equity Research
Humana (HUM) aims to expand the reach of its Medicare plans across newer U.S. counties in 2024 through integrating multiple lucrative benefits within them.
Alcon (ALC) Loses -6.61% in 4 Weeks, Here's Why a Trend Reversal May be Around the Corner
by Zacks Equity Research
Alcon (ALC) has become technically an oversold stock now, which implies exhaustion of the heavy selling pressure on it. This, combined with strong agreement among Wall Street analysts in revising earnings estimates higher, indicates a potential trend reversal for the stock in the near term.
Protect Your Portfolio From Volatility With 3 Low-Beta Picks
by Indrajit Bandyopadhyay
At this stage, it is prudent to invest in low-beta stocks with a favorable Zacks Rank like ALC, RDY and ANIK, as these will be less volatile than the broader market.
Here's Why Investors Should Retain Acadia Healthcare (ACHC)
by Zacks Equity Research
Acadia Healthcare (ACHC) is well-poised for growth on the solid demand for behavioral healthcare services, the continuous pursuit of expansion initiatives and growing cash reserves.
Is Alcon (ALC) Outperforming Other Medical Stocks This Year?
by Zacks Equity Research
Here is how Alcon (ALC) and Molina (MOH) have performed compared to their sector so far this year.
Here's Why Investors Should Buy Alcon (ALC) Stock Right Now
by Zacks Equity Research
Investors continue to be optimistic about Alcon (ALC) on the impressive performance of its portfolio.
Alcon (ALC) Gains From Innovation & International Expansion
by Zacks Equity Research
Alcon's (ALC) Surgical business continues to gain from diverse portfolio and incremental innovation.
Top Stock Reports for Visa, Chubb & HCA Healthcare
by Sheraz Mian
Today's Research Daily features new research reports on 16 major stocks, including Visa Inc. (V), Chubb Limited (CB) and HCA Healthcare, Inc. (HCA).
Waters (WAT) Walk-Up Solutions Boost Bioprocess Development
by Zacks Equity Research
Waters (WAT) launches new bioprocess walk-up solutions, automating sample prep and analysis from any bioreactor.
Here's Why You Should Retain Centene (CNC) in Your Portfolio
by Zacks Equity Research
Strong growth in membership, contract wins, accretive acquisitions and streamlining of businesses poise Centene (CNC) well for growth.
Alcon (ALC) Surgical Advances With New Data on AcrySof IQ Vivity
by Zacks Equity Research
Alcon's (ALC) Vivity Registry study data highlights the lens's versatility in treating a wide range of patients.
Community Health (CYH), Mindoula to Offer Mental Health Care
by Zacks Equity Research
Community Health (CYH) collaborates with Mindoula to enhance the availability of behavioral health resources to its affiliated provider network, who can now treat patients better.
Are Options Traders Betting on a Big Move in Alcon (ALC) Stock?
by Zacks Equity Research
Investors need to pay close attention to Alcon (ALC) stock based on the movements in the options market lately.
Are Medical Stocks Lagging Adagene (ADAG) This Year?
by Zacks Equity Research
Here is how Adagene Inc. Sponsored ADR (ADAG) and Alcon (ALC) have performed compared to their sector so far this year.
3 MedTech Stocks to Bet on Potential Pause of Rate Hike by Fed
by Indrajit Bandyopadhyay
Interest rates impact the healthcare industry and medical device companies in various ways. Here we discuss three companies HCA, ALC and SEM that are likely to gain potential pause in rate hikes.
Centene (CNC) Divests Circle Health Group, Optimizes Portfolio
by Zacks Equity Research
Centene (CNC) announces the sale of Circle Health Group to PureHealth in a bid to dispose of non-core assets and grow its core Managed Care business.
Cigna (CI) Eases Care Delivery With Prior Authorization Removal
by Zacks Equity Research
Cigna's (CI) branch, Cigna Healthcare, lifts the prior authorization requirement on 600-plus medical services, thereby easing administrative burdens and making way for simplified care delivery.
Has Alcon (ALC) Outpaced Other Medical Stocks This Year?
by Zacks Equity Research
Here is how Alcon (ALC) and RxSight, Inc. (RXST) have performed compared to their sector so far this year.